Samco Large & Mid Cap Fund
The scheme seeks to generate long-term capital appreciation from a diversified portfolio of predominantly Large Cap and Mid Cap equity and equity-related securities.
Growthvine rating: 1/5 — ranked #39 of 41 in category.
Fund basics
| Category | Equity: Large & Mid Cap |
|---|
| NAV | ₹9.36 (as of 2026-11-13) |
|---|
| AUM | ₹91 Cr |
|---|
| Expense ratio | 2.10% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Dhawal Ghanshyam Dhanani |
|---|
| Exit load | 1% for redemption within 30 days |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −17.37% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 37.2% of NIFTY LargeMidcap 250's upside and 79.5% of its downside.
Market cap allocation
| Large cap | 47.3% |
|---|
| Mid cap | 39.5% |
|---|
| Small cap | 13.2% |
|---|
Concentration
| Top 5 holdings | 33.4% |
|---|
| Top 10 holdings | 52.5% |
|---|
| Total holdings | 46 |
|---|
| Index overlap | 10.9% |
|---|
| Active share | 89.1% |
|---|
Top holdings
- Laurus Labs Limited — 10.3%
- National Stock Exchange Of India Limited — 9.3%
- Clearing Corporation of India Ltd — 8.8%
- Adani Energy Solutions Limited — 4.8%
- HITACHI ENERGY INDIA LIMITED — 4.6%
- Bharat Heavy Electricals Ltd. — 4.5%
- Divis Laboratories Ltd. — 4.2%
- Zydus Lifesciences Limited November 2026 Future — 3.8%
- Aurobindo Pharma Ltd. — 3.8%
- Federal Bank Ltd. — 3.7%
Top sectors
- Derivatives — 23.6%
- Pharma & Biotech — 21.2%
- Banking & Financial — 19.8%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 1.5% | Q3 | #22 of 38 |